Drug facts

Tirzepatide and constipation

Quick answer

It is common and it is in the label. In the obesity trials 17% of participants reported constipation at 5 mg, 14% at 10 mg and 11% at 15 mg, against 5% on placebo. The side-effects table puts those rates beside other reactions from the same trials. The figures do not establish why the rates differed by dose group.

How common it was1

Constipation is one of twelve reactions the approved label reports in 5% or more of trial participants. Its rates, pooled from the two pivotal obesity trials and shown by dose with the placebo column beside them:

Constipation reported at least once, by dose, against placebo.
Placebo5 mg10 mg15 mg
5%17%14%11%

The placebo column is the part worth reading. One person in twenty reported constipation without the drug at all, so the number that describes tirzepatide is the difference — roughly twelve points at 5 mg, falling to six at 15 mg — not the headline percentage.

For scale, it sits below nausea (25–29%) and diarrhea (19–23%), which rises with dose where constipation falls, and above vomiting (8–13%). The full table of reported reactions →

It gets less common at higher doses1

17% → 14% → 11% runs the opposite way to almost everything else in the table, and it is tempting to read it as the drug settling down. That is not what the numbers say.

The table reports adverse reactions by assigned dose in the pooled trials. The label does not establish why the constipation rates were lower in the higher-dose groups. These figures cannot predict whether an individual’s symptoms would improve at a higher dose.

What the label says about digestion2

The label states, in the section on interactions with oral medicines, that tirzepatide delays gastric emptying — food leaves the stomach more slowly. The label describes this effect when discussing absorption of oral medicines. It does not establish what caused the difference in constipation rates between dose groups.

The label raises delayed gastric emptying as a reason it can affect oral medicines, including oral contraceptives, rather than as an explanation for constipation. What the label says about interactions →

When it is not just constipation3

The same label describes, separately from the common-reaction table, risks that include severe gastrointestinal disease, acute pancreatitis and acute gallbladder disease. Those are not rated by frequency here, because a percentage is the wrong tool for them: any of them is a reason to contact a prescriber rather than to consult a table.

This page reports how often constipation was recorded in trials. It cannot tell you whether what you are experiencing is that.

What none of this covers

On the label — Mounjaro / Zepbound

These rates come from controlled trials of the approved product, at known doses, with an approved manufacturing process behind every injection.

In a compounded vial

No equivalent trial data exists for a compounded preparation. The molecule should behave like the molecule, but concentration and excipients differ between compounders, and nothing about those is covered by these numbers. What is actually different →

Nothing here is medical advice, and this page deliberately suggests no remedy. Whether a side effect needs managing, and how, is a question for the prescriber who wrote the prescription. See the medical disclaimer.

Sources

  1. FDA prescribing information for ZEPBOUND (tirzepatide), section 6.1, revision 8/2026 DailyMed
  2. FDA prescribing information for ZEPBOUND (tirzepatide), section 7.2, revision 8/2026 DailyMed
  3. FDA prescribing information for ZEPBOUND (tirzepatide), sections 5.2–5.4 and 6.2, revision 8/2026 DailyMed